We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Next-Generation Systems Introduced for Clinical Laboratories

By LabMedica International staff writers
Posted on 17 Aug 2016
A harmonized family of next-generation systems across immunoassay, clinical chemistry, point of care, hematology, blood and plasma screening and molecular diagnostics has been unveiled.

Many institutions and laboratories use multiple diagnostic platforms, often within a larger health care network and as they serve more patients and try to improve service levels with fewer qualified technicians, institutions are looking for new technologies that can help maximize testing efficiencies and help better manage resources.

The Alinity systems (Abbott Diagnostics, Abbott Park, IL, USA) will have the ability to work together, providing greater capacity and simplifying the user experience. More...
Several of the platforms will be designed to run more tests in less space, generate test results faster and minimize human errors. By offering a comprehensive solution that addresses the challenges of using multiple diagnostics platforms, while continuing to provide quality results that positively impact patient care, Alinity could potentially change the industry's testing paradigm.

Abbott expects Alinity launches to begin later this year and continue into 2017. The systems are supported by Abbott's AlinIQ, the first-of-its-kind, combined professional services and informatics solution that assists laboratories in achieving greater operational productivity with their existing resources. AlinIQ launched worldwide in April 2016. To develop each next-generation platform, Abbott's scientific and development teams engaged with thousands of clinicians, scientists, laboratory technicians and health care executives. The goal was to better understand their experiences and learn what is needed to address the challenges they face, whether in the core laboratory, at the point of care or in molecular diagnostics.

Dennis Gilbert, Ph.D., vice president at Abbott Diagnostics Products, said, “Abbott's Alinity systems are being built from the ground up based on customer insights, using the latest technologies suitable for testing today and in the future. Whether it's an easy-to-use software interface, running more tests faster or the ability to run any test at any time, our Alinity platforms are designed to include these features and more without any compromise in performance or quality.” The Alinity System was unveiled during the 68th AACC Annual Scientific Meeting & Clinical Lab Expo held July 31 to August 4, 2016, in Philadelphia, PA, USA.

Related Links:
Abbott Diagnostics
AACC Annual Scientific Meeting & Clinical Lab Expo

Gold Member
Ketosis and DKA Test
D-3-Hydroxybutyrate (Ranbut) Assay
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Human Estradiol Assay
Human Estradiol CLIA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.